BAX

Business profile & competitive position

Baxter International Inc. is a large-cap Healthcare company classified in the Medical - Instruments & Supplies industry. Through its subsidiaries, it develops and supplies a broad portfolio of essential products: sterile intravenous solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostats and sealants, advanced surgical equipment, smart beds, patient monitoring and diagnostic technologies, and respiratory health devices. Its customers include hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, physicians’ offices, kidney dialysis centers, and at-home patients under physician supervision.

Since implementing a new operating model in the third quarter of 2023, Baxter has reported through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. After the January 2025 sale of the Kidney Care business, Baxter manufactured in more than 20 countries and sold products in more than 100 countries as of December 31, 2025.

The current profitability figures, however, do not suggest a strong near-term moat. Baxter’s net margin is negative 9.3% and its return on equity is negative 16.6%, meaning the business is currently generating net losses rather than excess returns. Its beta of 0.59 indicates lower stock-price volatility than the overall market, consistent with a defensive healthcare supplier, but that relative stability is not the same as pricing power.

Financial posture

Baxter carries a market capitalization of $12.4 billion and currently trades at a negative P/E of -11.7. A negative P/E is not an expansion premium; it is a mathematical consequence of trailing losses, which aligns with the negative 9.3% net margin and negative 16.6% ROE.

The balance-sheet focus is debt reduction. In January 2025, Baxter completed the sale of its Kidney Care business to Carlyle for an aggregate purchase price of $3.80 billion in cash. The company applied the net proceeds primarily to repay approximately $3.81 billion of legacy indebtedness during 2025. Management’s stated capital-allocation priority is to retain an investment-grade credit rating and reach a net leverage target of roughly 3.0x by year-end 2026, while continuing to pay dividends and remaining selective on acquisitions and share repurchases.

At the current snapshot, the stock is priced at $23.96, with an RSI of 35.4 and a 50-day exponential moving average of $24.56—contextual data points that show the shares sitting just below a near-term moving average and near technically oversold territory.

Strategic priorities & outlook

Baxter’s most recent 10-K outlines four operational priorities:

• Innovation-led growth. Accelerate sales growth through connected-care offerings such as smart beds, infusion pumps, patient monitoring and diagnostics, respiratory devices, and surgical equipment, plus targeted investment in higher-growth markets and core therapies.
• Portfolio management. Actively manage the portfolio through acquisitions, divestitures, strategic market exits, and channel expansion to maximize stockholder value and support profitability objectives.
• Operational simplification. Streamline the organization by eliminating managerial layers, automating processes, digitizing workflows, and exploring artificial intelligence initiatives.
• Capital discipline. Direct capital toward debt repayment to defend the investment-grade rating and hit the ~3.0x net leverage target by year-end 2026, while continuing dividends and being highly selective on acquisitions and buybacks.

In short, Baxter’s near-term story is a mix of portfolio reshaping, cost restructuring, and debt repair rather than pure organic expansion.

Macro & geopolitical exposure

As a Medical - Instruments & Supplies business, Baxter operates in one of the most regulated industries in the world. Its exposures include:

• Regulatory and reimbursement risk. Medical devices, pharmaceuticals, and diagnostics are subject to FDA and global health-authority oversight, quality-system requirements, and evolving reimbursement rules that can affect demand and pricing.
• Currency exposure. Because a significant portion of revenue is generated outside the United States and products are sold in more than 100 countries, foreign-exchange swings can influence reported results.
• Trade and supply-chain exposure. Manufacturing across more than 20 countries creates potential tariff, logistics, and input-cost risks, especially for electronic components and sterile disposables.
• Hospital capital spending. Demand for smart beds, monitoring systems, and surgical equipment is indirectly linked to hospital budgets, which can tighten during periods of macroeconomic pressure or public-policy uncertainty.

Recent developments

Recent headlines illustrate the themes shaping the stock’s narrative. On September 7, 2026, Zacks reported that “BAX Raises 2026 Outlook as Strong Q2 Growth Offsets Margin Pressure,” underscoring that the market is focused on whether top-line momentum can outrun cost pressures. On September 9, 2026, Seeking Alpha published the transcript of Baxter’s presentation at the Wells Fargo 21st Annual Healthcare Conference, giving investors direct access to management commentary on strategy and financial targets.

On September 10, 2026, Defenseworld.net ran a head-to-head analysis comparing TELA Bio and Baxter International, reflecting continued investor interest in benchmarking the company against smaller med-tech peers. Separately, a September 8, 2026, GuruFocus piece on Richard Pzena’s purchase of Globant SA appeared in the same value-investing news flow as coverage of Baxter, highlighting the broader contrarian screen in which the stock frequently appears given its compressed valuation metrics.

Earnings behavior & post-earnings drift

Baxter’s earnings track record over the last eight quarters shows a 75% beat rate (6 out of 8) and an average surprise of 11.4%. Across those same quarters, the average 5-day price move following an earnings report is +2.41%, classified as an upward post-earnings drift.

The most recent four quarters reveal how complicated that drift can be:

• July 30, 2026: Actual EPS of $0.56 versus the $0.3665 estimate, a 52.8% beat. The stock fell 2.21% the next day but drifted up 0.97% over the following five sessions.
• April 30, 2026: Actual EPS of $0.36 versus the $0.311 estimate, a 15.8% beat. The stock dropped 2.1% the next day and slid 0.51% over the next five sessions.
• February 12, 2026: Actual EPS of $0.44 versus the $0.53 estimate, a 17.0% miss. The stock rallied 5.77% the next day and surged 15.34% over the following five sessions.
• October 30, 2025: Actual EPS of $0.69 versus the $0.60 estimate, a 15.0% beat. The stock fell 3.6% the next day and declined 6.16% over the next five sessions.

The pattern shows that beats have not automatically produced positive next-day reactions, while the lone miss in this window produced a substantial relief rally. The next scheduled report is October 29, 2026, before the open, with the current consensus EPS estimate at $0.52.

For a deeper look at how sell-side and institutional models are currently weighing Baxter’s restructuring progress, debt trajectory, and upcoming October 2026 earnings report, review the full institutional verdict on the ticker page.